OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Recommendation of "Hold" by Brokerages

Key Points

• Analyst consensus: Six brokerages give OPKO a consensus "Hold" rating (1 sell, 4 hold, 1 strong buy) with an average 12‑month price target of $1.55.
• Recent quarter: OPKO reported EPS of ($0.07) which matched estimates, but revenue of $124.2M missed the $130.5M consensus and was down 17.1% year‑over‑year, with negative net margin and ROE; analysts project ~($0.27) EPS for the current fiscal year.
• Stock snapshot: OPK opened at $1.13 with a market cap of $853.25M, a 1‑year range of $0.98–$1.60, and about 64.63% institutional ownership.

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) has earned an average recommendation of "Hold" from the six brokerages that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $1.55.

A number of equities research analysts have weighed in on OPK shares. Weiss Ratings restated a "sell (d-)" rating on shares of OPKO Health in a research note on Tuesday, April 21st. Wall Street Zen cut OPKO Health from a "hold" rating to a "sell" rating in a research note on Saturday, March 7th. Finally, Barrington Research downgraded shares of OPKO Health from an "outperform" rating to a "market perform" rating in a research report on Wednesday, April 29th.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Caprock Group LLC bought a new stake in shares of OPKO Health in the 3rd quarter worth about $26,000. Swiss Life Asset Management Ltd bought a new position in shares of OPKO Health during the third quarter worth about $30,000. Zacks Investment Management bought a new position in shares of OPKO Health during the fourth quarter worth about $27,000. Savant Capital LLC acquired a new position in OPKO Health in the third quarter worth about $33,000. Finally, StoneX Group Inc. bought a new stake in OPKO Health in the fourth quarter valued at about $27,000. 64.63% of the stock is currently owned by institutional investors.

OPKO Health Stock Performance

NASDAQ:OPK opened at $1.13 on Wednesday. The firm has a 50-day moving average of $1.18 and a two-hundred day moving average of $1.27. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.61 and a quick ratio of 3.17. The stock has a market cap of $853.25 million, a P/E ratio of -4.19 and a beta of 1.42. OPKO Health has a 1-year low of $0.98 and a 1-year high of $1.60.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its earnings results on Tuesday, April 28th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.07). OPKO Health had a negative return on equity of 16.78% and a negative net margin of 36.63%.The business had revenue of $124.20 million for the quarter, compared to analyst estimates of $130.51 million. During the same period in the previous year, the company earned ($0.10) earnings per share. The company's revenue for the quarter was down 17.1% compared to the same quarter last year. On average, research analysts expect that OPKO Health will post -0.27 earnings per share for the current fiscal year.

About OPKO Health

OPKO Health, Inc NASDAQ: OPK is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.